| Name | BDA-366 | 
|---|---|
| Synonyms | 
                                
                                9,10-Anthracenedione, 1-[[(2S)-3-(diethylamino)-2-hydroxypropyl]amino]-4-[[(2S)-oxiranylmethyl]amino]-
                                
                                
                                 BDA-366 1-{[(2S)-3-(Diethylamino)-2-hydroxypropyl]amino}-4-{[(2S)-2-oxiranylmethyl]amino}-9,10-anthraquinone  | 
                        
| Description | BDA-366 is a potent Bcl2 antagonist (Ki = 3.3 nM), binding Bcl2-BH4 domain with high affinity and selectivity. BDA-366 induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer cells[1]. | 
|---|---|
| Related Catalog | |
| Target | 
                                
                                 Bcl-2:3.3 nM (Ki)  | 
                        
| References | 
| Density | 1.3±0.1 g/cm3 | 
|---|---|
| Boiling Point | 669.4±55.0 °C at 760 mmHg | 
| Molecular Formula | C24H29N3O4 | 
| Molecular Weight | 423.50 | 
| Flash Point | 358.6±31.5 °C | 
| Exact Mass | 423.215820 | 
| LogP | 2.18 | 
| Vapour Pressure | 0.0±2.1 mmHg at 25°C | 
| Index of Refraction | 1.665 | 
| Storage condition | -20℃ |